-

01:33:30 AM

Latest LCTX Stock Market News

LCTX - Lineage Cell Therapeutics Inc

09/15/21 9:00 AM

AMEX : LCTX

clinical trial

Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported updated interim results from its ongoing, 24- patient Phase 1/ 2 a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment...

RHEA-AI

neutral

09/13/21 8:00 AM

AMEX : LCTX

Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported today that updated interim results from a Phase 1/ 2 a study of its lead product candidate, OpRegen ®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry...

RHEA-AI

neutral

09/01/21 8:00 AM

AMEX : LCTX

management

Lineage Announces Appointment of General Counsel

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage’ s General Counsel and Corporate Secretary. Mr. Samuel has also practiced corporate law at major law firms, including DLA Piper LLP and Cooley LLP, where he...

RHEA-AI

very positive

08/12/21 4:05 PM

NYSE : LCTX

earnings

Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter 2021. Lineage will host a conference call today at 4:30 p.m.

RHEA-AI

positive

08/10/21 8:00 AM

NYSE : LCTX

conferences

Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be participating in and presenting at the H.C.

RHEA-AI

neutral

08/05/21 8:00 AM

NYSE : LCTX

conferencesearnings

Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2021 financial and operating results on Thursday, August 12, 2021, following

RHEA-AI

neutral

07/20/21 8:00 AM

NYSE : LCTX

clinical trial

OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported updated interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen.

RHEA-AI

neutral

07/13/21 8:00 AM

NYSE : LCTX

OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen ® , a retinal pigment

RHEA-AI

neutral

06/28/21 8:00 AM

NYSE : LCTX

Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has been added to both the broad-market Russell 3000 ® Index as well as the Russell Microcap ® Index.

RHEA-AI

neutral

06/22/21 6:50 AM

NYSE : LCTX

Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on the clinical advancement of OPC1, its investigational allogeneic oligodendrocyte progenitor cell (OPC)

RHEA-AI

positive

LCTX Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitelineagecell.com
CeoBrian Culley
Security nameLineage Cell Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees52
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address2173 Salk Ave Ste 200
StateCalifornia
CityCarlsbad
Zip92008-7354
CountryUS
Phone15105213390

LCTX Description:

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical programs are in markets with billion dollar opportunities and include three allogeneic ('off-the-shelf') product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer.